Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer.
Fengchun MuBingjie FanHaoqian LiWenru QinChunni WangBing ZouLinlin WangPublished in: Future oncology (London, England) (2023)
Background: The present study evaluated the efficacy and safety of nab-paclitaxel (nab-PTX) with a concurrent PD-1/PD-L1 inhibitor in patients with refractory relapsed small-cell lung cancer (SCLC). Patients & methods: We retrospectively analyzed 240 patients with refractory relapsed SCLC: 40 patients were treated with nab-PTX plus PD-1/PD-L1 inhibitor, and 200 received traditional chemotherapy. Results: Median progression-free survival in the nab-PTX plus PD-1/PD-L1 inhibitor and traditional chemotherapy groups was 3.6 and 2.5 months (p = 0.0021), respectively. The median overall survival was 8.0 and 5.2 months (p = 0.0002), respectively. No new safety issues were identified. Conclusion: Nab-PTX plus PD-1/PD-L1 inhibitor significantly improved survival in patients with refractory relapsed SCLC compared with traditional chemotherapy.
Keyphrases
- small cell lung cancer
- free survival
- acute lymphoblastic leukemia
- advanced non small cell lung cancer
- acute myeloid leukemia
- end stage renal disease
- newly diagnosed
- diffuse large b cell lymphoma
- multiple myeloma
- ejection fraction
- locally advanced
- hodgkin lymphoma
- chronic kidney disease
- squamous cell carcinoma
- tyrosine kinase